课题基金 / 基金详情

PHASE I STUDY OF BMS-188667 IN PATIENTS WITH PSORIASIS VULGARIS

PHASE I STUDY OF BMS-188667 IN PATIENTS WITH PSORIASIS VULGARIS
BMS-188667 在寻常型银屑病患者中的 I 期研究
批准号：
5218444
负责人：
BRIAN JEGASOTHY
金额：
$0.0万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/5218444
关键词：
artificial immunosuppression clinical research clinical trial phase I dosage drug screening /evaluation human subject human therapy evaluation immunosuppressive intravenous administration longitudinal human study psoriasis skin disorder chemotherapy

项目摘要

项目成果

BRIAN JEGASOTHY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a phase I:II open-label study assesses the safety, efficacy, and biologic activity of BMS-188667 in patients with 10-40% body surface area of psoriasis vulgaris. BMS-188667 is an investigational drug that selectively blocks the second signal in T cell activation. Increasing evidence suggests that T-cell is involved in the pathogenesis of this disease. Patients will receive four intravenous doses of BMS-188667, and be evaluated for safety and efficacy in follow-up for a total period of 99 days.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE III RANDOMIZED TRIAL OF TWO DOSE DA389IL-2 IN CTCL <3 PREVIOUS TREATMENTS
PHASE I STUDY OF BMS-188667 IN PATIENTS WITH PSORIASIS VULGARIS
MULTICENTER PHASE 3 TRIAL OF DAB3891L-2 IN CTCL PATIENTS IN STAGE IA-IVA DISEASE
PHASE III RANDOMIZED TRIAL OF TWO DOSE DA389IL-2 IN CTCL <3 PREVIOUS TREATMENTS
海外基金